Therapeutic Areas ace

Inquiry

* First Name
* Last Name
* Business Email
Phone
Company/Institution
Job Title
* Services or Products of Interest Diabetic Retinopathy Pathological Research Service
When do you expect your project to start?
Project Description
* All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
* Tick to confirm the Research Use Only (RUO) statement.

Diabetic Retinopathy Pathological Research Service

Among the numerous complications induced by diabetes, diabetic retinopathy (DR) stands as one of the leading causes of adult blindness. In-depth exploration of its pathological mechanisms is critical for advancing disease research and therapeutic development. Ace Therapeutics, as a preclinical contract research organization in the field of diabetes, provides one-stop research services on the pathogenesis of diabetic retinopathy to help make innovative breakthroughs in the field of diabetic retinopathy, based on our deep industry accumulation and advanced technology.

Introduction to Diabetic Retinopathy

The pathology of diabetic retinopathy is complex, involving multiple levels of retinal vascular endothelial cell dysfunction, nerve cell apoptosis, activation of inflammatory responses, and oxidative stress triggered by metabolic abnormalities. As the disease progresses, microaneurysms, vascular leakage, and neovascularization occur in the retina, ultimately leading to severe visual impairment and even blindness. Currently, there are limited effective treatments for DR, and the underlying reason is that its pathologic mechanism has not yet been fully understood. In-depth research on the patho-mechanism of DR is of great significance to both basic scientific research to reveal the nature of the disease and to drug companies to develop innovative therapies.

Fig. 1 Schematic overview of pathogenic mechanisms leading to the sight-threatening endpoints of DR. (Lechner, J.; et al., 2017)

Diabetc Retinopathy Pathological Research Services at Ace Therapeutics

From cross-species model libraries to dynamic pathological profiling and molecular mechanism deciphering, our vertically integrated platform delivers physiologically relevant and clinically predictive DR model

Services	Introduction
Diabetic retinopathy modeling services	Rodents: model of STZ-induced diabetes, Ins2Akita transgenic mouse, OIR (Oxygen Induced Retinopathy) model Non-human primates: long-term tracking model of spontaneous diabetic rhesus monkeys Class organ: 3D retinal vascular-neural unit co-culture system
Diabetic retinopathy model validation services	With the combined use of continuous glucose monitoring (CGM) and fundus imaging, the entire pathological process from the development of microangiomas to macular edema and progression to fibroplasia can be induced in a controlled manner.
Molecular mechanisms deep dive	Blood-retinal barrier study
In vitro BRB modeling	High-throughput permeability assessment (TEER value monitoring + fluorescent tracer leakage assay). Mechanical stress simulation (hyperglycemic/hypoxic/inflammatory factor multiple stimulation system).
In vivo visualization techniques	Two-photon microimaging for real-time observation of vascular leakage. Molecular probe labeling of tight junction proteins (ZO-1, occludin) dynamic changes.

Advantages of Our Diabetic Retinopathy Pathological Research Services

Bridging cutting-edge technology with multidimensional insights, our integrated research platform empowers breakthroughs in diabetic retinopathy (DR) pathology.

Advanced laboratory equipment

We provide advanced laboratory equipment, including fully automated paraffin slicers, laser confocal microscopes and digital pathology scanners.

Intelligent data analysis platform

We utilize bioinformatics tools to integrate pathological data with transcriptomic and proteomic data to explore the potential regulatory network of pathological mechanisms, thus enhancing research efficiency and analysis accuracy.

Multi-omics research platform

We combine pathology analysis with genomics (e.g. whole genome sequencing), transcriptomics (RNA-seq), and proteomics (mass spectrometry) technologies to comprehensively analyze the regulatory mechanisms in the process of DR occurrence and development from the molecular, cellular, and tissue levels, and to provide our clients with multi-level and systematic research data.

Ace Therapeutics is committed to applying our expertise to facilitate the rapid translation and application of research findings on the pathomechanisms of DR. Please contact us for more details and we will be happy to assist you.

References

Lechner, J.; et al. The pathology associated with diabetic retinopathy. Vision research. 2017, 139: 7-14.
Antonetti, D. A.; et al. Current understanding of the molecular and cellular pathology of diabetic retinopathy. Nature Reviews Endocrinology. 2021, 17(4): 195-206.
Stitt, A. W.; et al. The progress in understanding and treatment of diabetic retinopathy. Progress in retinal and eye research. 2016, 51: 156-186.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Services